Oxford Vacmedix raises $12.5M series A

Oxford Vacmedix UK Ltd. (Oxford, U.K.) raised $12.5 million in a series A round from Cancer Rop Co. Ltd. (KOSDAQ:180400) and undisclosed existing Chinese investors.

The company's OVM-100 and OVM-200 are in preclinical testing to treat cervical cancer and solid tumors, respectively. OVM-100 is an HPV vaccine, and OVM-200 is a vaccine using survivin (BIRC5)...